1187451-41-7

Usage

Uses

Used in Pharmaceutical Industry:
(6-((4-(pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid is used as a pharmaceutical agent for the treatment of specific conditions. Its unique structure allows it to interact with biological targets, such as receptors or enzymes, to modulate their activity and produce therapeutic effects.
Used in Glaucoma Treatment:
In the context of glaucoma treatment, (6-((4-(pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid is used as a selective, non-prostanoid EP2 receptor agonist. This application is based on its ability to modulate the EP2 receptor, which plays a role in the regulation of intraocular pressure. By targeting this receptor, the compound can help reduce intraocular pressure and alleviate the symptoms of glaucoma.

Upstream product

• 143426-49-7 1-(4-hydroxymethylphenyl)-1H-pyrazole 
• 1187450-65-2 tert-butyl (tert-butoxycarbonyl(6-((4-(pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-yl)amino)acetate 
• 1187451-32-6 tert-butyl [(6-aminomethylpyridin-2-yl)tert-butoxycarbonylamino]acetate 
• 1187451-30-4 tert-butyl [tert-butoxycarbonyl(6-hydroxyiminomethylpyridin-2-yl)amino]acetate 
• 1187451-25-7 tert-butyl [tert-butoxycarbonyl(6-ethoxycarbonylpyridine-2-yl)amino]acetate 
• 1187451-29-1 tert-butyl [tert-butoxycarbonyl(6-formylpyridin-2-yl)amino]acetate 
• 1187450-77-6 tert-butyl (tert-butoxycarbonyl{6-[(pyridin-3-ylsulfonyl)aminomethyl]pyridin-2-yl}amino)acetate 
• 1187450-49-2 tert-butyl (tert-butoxycarbonyl(6-(hydroxymethyl)pyridin-2-yl)amino)acetate 
• 203321-86-2 6-tert-butoxycarbonylamino-pyridine-2-carboxylic acid ethyl ester 

Downstream Products

• 1273387-12-4 (2,2,2-trifluoroethyl) (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate 
• 1187451-19-9 isopropyl 2-{[6-({N-[4-(1H-pyrazol-1-yl)benzyl]pyridine-3-sulfonamido}methyl)pyridin-2-yl]amino}acetate 

Relevant academic research and scientific papers

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl

EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects. Through medicinal chemistry efforts, we identified a scaffold bearing a (pyridin-2-ylamino)acetic acid moiety as a promising EP2-selective receptor agonist. (6-((4-(Pyrazol-1-yl)benzyl)(pyridin-3-ylsulfonyl)aminomethyl)pyridin-2-ylamino)acetic acid 13ax (omidenepag, OMD) exerted potent and selective activity toward the human EP2 receptor (h-EP2). Low doses of omidenepag isopropyl (OMDI), a prodrug of 13ax, lowered intraocular pressure (IOP) in ocular normotensive monkeys. OMDI was selected as a clinical candidate for the treatment of glaucoma.

SUBSTITUTED CARBONYL COMPOUNDS

This is to provide a novel substituted carbonyl compound represented by the following formula (I) having an excellent bronchodilatory action based on potent EP2 agonistic action and useful for treatment of respiratory diseases. A compound represented by t